
Learn how testosterone becomes estradiol, what controlled research found about their roles, and which questions to bring to a clinician.

Testosterone-to-estradiol conversion is the process in which an enzyme called aromatase changes some testosterone into estradiol, an estrogen that has physiological roles in men.
Estradiol is therefore not simply waste left over from testosterone production. Research in men has connected estrogen deficiency with changes in body fat and sexual function. Understanding how these hormones are connected starts with that distinction: conversion is part of the biology being assessed, not evidence that estrogen is inherently undesirable.
This article is for informational purposes only and is not medical advice. A qualified clinician should interpret personal symptoms and hormone results and make treatment decisions.
Clinical reference ranges and individual treatment goals are not the same as findings from an experiment. The useful question here is what the research establishes about hormone function before applying it to a personal result.
In 2013, a controlled study reported in the New England Journal of Medicine examined 400 healthy men aged 20 to 50. Researchers suppressed participants' hormone production and gave varying amounts of testosterone. Some participants also received an aromatase inhibitor to reduce estrogen production.
The design addressed a specific question: which changes were associated with androgen deficiency and which with estrogen deficiency? Looking at the pathways separately helped distinguish their contributions to the outcomes being measured.
The study lasted 16 weeks and involved healthy younger men under experimental hormone suppression. Its findings are not direct predictions for every older man or every man receiving testosterone replacement therapy (TRT). It did not establish a precise estradiol threshold that is safe or optimal for an individual.
For clinical interpretation, this means the findings are evidence about function rather than a numerical interval to use for self-assessment. Biologically, the study concerned what happened when androgen or estrogen availability was reduced. It was not a ranking of every possible blood-test value.
A useful discussion separates the laboratory question from the symptom question. One asks what was measured. The other asks whether the result helps explain the concern. Those questions are related, but neither is answered merely by knowing that testosterone can convert to estradiol.
Questions about how different testosterone measurements fit together belong in the same discussion with a clinician. The focus should be what the result means for the concern being evaluated and what further assessment would clarify. Lowering estradiol simply because it is an estrogen does not follow from these findings.
The study found different patterns for physical changes and sexual function. These patterns help explain why neither testosterone nor estradiol should be treated as the sole hormone relevant to every complaint.
Androgen deficiency was associated with losses in lean mass, muscle size and strength. These findings connect reduced androgen activity with several physical outcomes rather than with one general feeling of being unwell.
The practical distinction is between the measured outcomes: lean mass, muscle size and strength were not the same finding as increased body fat.
Estrogen deficiency was associated mainly with increased body fat. That finding challenges the assumption that less estrogen must always be better for men.
It also changes how the conversion pathway should be understood. Estradiol formation is not just a side issue to dismiss while focusing on testosterone's physical effects.
Both androgen and estrogen deficiency contributed to declines in sexual function. This was the clearest example in the study of an outcome linked to both hormone pathways.
These deficiency findings are not a symptom checklist for either low or high estradiol. Physical changes and sexual concerns require clinical assessment rather than a hormone label chosen from a symptom. The distinction between a change in desire and a testosterone diagnosis is especially relevant here.
When discussing the findings, it helps to name the actual concern rather than use “hormone imbalance” as a catch-all. A change in strength and a change in sexual function were different outcomes in this research. Keeping those concerns distinct gives a clinician a clearer question to assess.
The 2026 European Association of Urology guideline says testosterone therapy may benefit several aspects of sexual life in men with hypogonadism. It reports no evidence for using testosterone therapy to treat sexual dysfunction in eugonadal men, meaning men with normal testosterone status.
That distinction matters: evidence supporting a treatment in men with diagnosed deficiency should not be extended automatically to men without that deficiency.
The same guideline says available evidence is insufficient to determine whether testosterone therapy alone affects fracture risk. That is a separate outcome from sexual function or body composition. A biological role for a hormone should not be turned into a claim that a treatment prevents fractures.
The biological and medical inputs in this evidence involve hormone production and conversion. The experiment changed those processes directly rather than testing a lifestyle routine.
The use of an aromatase inhibitor is easy to misread. In this study, its purpose was to reduce estrogen production so researchers could compare outcomes. Its inclusion is not a recommendation for men who are concerned about estradiol or are already receiving TRT.
These inputs describe the research design, not instructions to alter testosterone use or add a medicine that reduces estrogen. Studying a blocked conversion pathway is different from showing that blocking it benefits a particular patient.
The findings also do not justify a specific food, supplement or exercise plan for adjusting estradiol. A claim about an everyday habit needs evidence about that habit, not just evidence that estradiol has a physiological role.
For a man discussing testing or TRT, the useful focus is the clinical reason for measuring or changing a hormone. Understanding the conversion pathway helps frame that discussion without making a laboratory number the goal in itself.
Ask your physician: “Which reference ranges apply to my results? Do my symptoms suggest that further assessment is needed? Would measuring estradiol help answer a specific clinical question? How would that information change my care?”
Testosterone conversion can be explained without assuming that a man's symptoms reveal which hormone needs to change. For men uncertain about possible low testosterone, Testostra explains the evidence around symptoms and related biomarkers so hormone information becomes easier to understand without becoming an individual diagnosis or treatment plan.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra